Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
Among patients with severe, uncontrolled asthma, tezepelumab treatment was associated with an increased likelihood of achieving complete clinical response and on-treatment clinical remission compared with placebo. Both are clinically important outcomes, but may be driven by different patient characteristics.
Authors
- Guy Brusselle (ORCID: https://orcid.org/0000-0001-7021-8505)
- Njira Lucia Lugogo (ORCID: https://orcid.org/0000-0002-0235-7105)
- J. Christian Virchow (ORCID: https://orcid.org/0000-0003-4291-1956)
- Gillian Hunter (ORCID: https://orcid.org/0000-0002-1953-0058)
- Mario Castro (ORCID: https://orcid.org/0000-0001-6328-8994)
- Michael E. Wechsler (ORCID: https://orcid.org/0000-0003-3505-2946)
- ARNAUD AB BOURDIN (ORCID: https://orcid.org/0000-0002-4645-5209)
- Christopher Edward Brightling (ORCID: https://orcid.org/0000-0002-9345-4903)
- Κonstantinos Κostikas (ORCID: https://orcid.org/0000-0003-0774-3942)
- Stephanie L. Roseti
- David J. Jackson (ORCID: https://orcid.org/0000-0002-2299-868X)
- Ian Pavord (ORCID: https://orcid.org/0000-0002-4288-5973)
- Christopher S. Ambrose (ORCID: https://orcid.org/0000-0003-4175-7336)
- Jean‐Pierre Llanos (ORCID: https://orcid.org/0000-0002-7785-6881)
- Neil Martin (ORCID: https://orcid.org/0000-0003-3115-3328)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Centre National de la Recherche Scientifique (FR)
- Amgen (United States) (US)
- University of Kansas (US)
- University of Leicester (GB)
- Inserm (FR)
- King's College London (GB)
- University of Ioannina (GR)
- Université de Montpellier (FR)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- University of Michigan (US)
- Ghent University Hospital (BE)
- National Jewish Health (US)
- National Institute for Health and Care Research (GB)
- University of Oxford (GB)
- AstraZeneca (France) (FR)
- AstraZeneca (United States) (US)
- NIHR Leicester Biomedical Research Centre (GB)
- University of Rostock (DE)
- University of Colorado Denver (US)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1183/13993003.00316-2024
- Citations
- 35
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 11.43
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Teva Pharmaceutical Industries
- CSL Behring
- Regeneron Pharmaceuticals
- Vertex Pharmaceuticals
- National Jewish Health
- Deutsche Forschungsgemeinschaft
- Shionogi
- National Institutes of Health
- Genentech
- Cilag